{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462273886
| IUPAC_name = N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
<!--Clinical data -->
| tradename = originally Neulasta, other brand names worldwide<ref name=generic>Drugs.com [http://www.drugs.com/international/pegfilgrastim.html International brand names for pegfilgrastim] Page accessed April 1, 2016</ref>
| Drugs.com = {{drugs.com|monograph|pegfilgrastim}}
| MedlinePlus = a607058
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = Rx-only
<!-- Pharmacokinetic data -->
| elimination_half-life = 15–80 hrs
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 208265-92-3
| ATC_prefix = L03
| ATC_suffix = AA13
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00019
| IUPHAR_ligand = 6969
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3A58010674
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06889
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201568
<!-- Chemical data -->
| C=845 | H=1343 | N=223 | O=243 | S=9
| chemical_formula_comment = +&nbsp;PEG 
| molecular_weight = 39,000 g/mol
}}
'''Pegfilgrastim''' is a [[PEGylated]] form of the recombinant human [[granulocyte colony-stimulating factor]] (GCSF) analog [[filgrastim]]. It serves to stimulate the level of white blood cells ([[neutrophils]]).<ref>Walsh, G, Spada, S. "Epogen/Procrit" in: ''Directory of approved biopharmaceutical products''. CRC Press, 2005, pp. 136–37.</ref>

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.<ref name="Drugs.com" />

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).<ref>Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, pp. 139, 158.</ref><ref name="Drugs.com">Drugs.com: [http://www.drugs.com/monograph/pegfilgrastim.html Pegfilgrastim]</ref> 

In the United States as of 2015 the branded form costs between $5,327 and $8,191 a dose.<ref>{{cite news|last1=Langreth|first1=Robert|title=Decoding Big Pharma’s Secret Drug Pricing Practices|url=https://www.bloomberg.com/graphics/2016-drug-prices/|accessdate=15 July 2016|publisher=Bloomberg|date=June 29, 2016}}</ref>

==Biosimilars==
In July 2016 the [[US FDA]] rejected a biosimilar application from [[Sandoz]].<ref name=BPR1607>[http://www.biopharma-reporter.com/Markets-Regulations/US-FDA-rejects-Sandoz-Neulasta-biosimilar/ US FDA rejects Sandoz’s Neulasta biosimilar. 19 July 2016]</ref>

In 2016 Coherus BioSciences is running clinical studies on its own pegfilgrastim biosimilar CHS-1701.<ref name=BPR1607/>

==References==
{{Reflist}}

==External links==
* {{Official website|http://www.neulasta.com/|name=Neulasta}}
* [http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf Neulasta full prescribing information]
* [http://pi.amgen.com/united_states/neulasta/neulasta_ifu_hcp_pt_english.pdf Neulasta Onpro kit Healthcare Provider Instructions for Use]


{{Immunostimulants}}
{{Cytokine receptor modulators}}
{{Growth factor receptor modulators}}

[[Category:Immunostimulants]]
[[Category:Recombinant proteins]]


{{antineoplastic-drug-stub}}